Ligands with different dimeric configurations potently activate the EphA2 receptor and reveal its potential for biased signaling

The EphA2 receptor tyrosine kinase activates signaling pathways with different, and sometimes opposite, effects in cancer and other pathologies. Thus, highly specific and potent biased ligands that differentially control EphA2 signaling responses could be therapeutically valuable. Here, we use EphA2...

Descripción completa

Detalles Bibliográficos
Autores principales: Gomez-Soler, Maricel, Gehring, Marina P., Lechtenberg, Bernhard C., Zapata-Mercado, Elmer, Ruelos, Alyssa, Matsumoto, Mike W., Hristova, Kalina, Pasquale, Elena B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8858996/
https://www.ncbi.nlm.nih.gov/pubmed/35243233
http://dx.doi.org/10.1016/j.isci.2022.103870

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8858996/
https://www.ncbi.nlm.nih.gov/pubmed/35243233
http://dx.doi.org/10.1016/j.isci.2022.103870

Ejemplares similares